Genetic Testing Market Forecast: Expansion Across Clinical and Direct-to-Consumer Segments
Genetic Testing Market Forecast: Expansion Across Clinical and Direct-to-Consumer Segments
genetic testing market is rapidly expanding as healthcare shifts towards personalized and preventive medicine. With enhanced detection technologies, testing now spans a range of applications—from hereditary disease screening and cancer diagnostics to pharmacogenomic insights and ancestry analysis. Key trends include better accessibility, affordable pricing, and consumer-friendly at-home kits, making genetic testing more mainstream than ever.
According to Fortune Business Insights, the genetic testing market was valued at USD 33.82 billion in 2024. The market is projected to grow from USD 37.32 billion in 2025 to USD 76.09 billion by 2032, exhibiting a CAGR of 10.7% during the forecast period. In 2024, North America dominated the genetic testing market with a market share of 41.72%.
Hoffmann-La Roche Ltd. (Switzerland)
Illumina, Inc. (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
Oxford Nanopore Technologies plc. (U.K.)
Laboratory Corporation of America Holdings (U.S.)
Agilent Technologies, Inc. (U.S.)
Myriad Genetics, Inc. (U.S.)
QIAGEN (Germany)
Quest Diagnostics Incorporated (U.S.)
Danaher Corporation (U.S.)
In May 2023, Laboratory Corporation of America (LabCorp) expanded its specialty lab testing capabilities through a strategic agreement with Jefferson Health. This collaboration enhances advanced genetic testing accessibility, supporting more robust diagnostic and personalized treatment services.
Market Drivers:
Increasing Prevalence of Chronic Diseases: With cancer, cardiovascular disorders, and rare conditions on the rise, the need for early diagnosis via genetic testing grows .
Advancements in Technologies: Breakthroughs in Next-Generation Sequencing (NGS), microarrays, and PCR are improving test speed, accuracy, and affordability .
Growth of Personalized Medicine: Tailoring treatments based on genetic data—from oncology to pharmacogenomics—increases demand for sophisticated genetic tests .
Direct-to-Consumer Testing: Rising consumer awareness of ancestry and health risk testing is further boosting market growth.
Restraints:
High Costs: Many advanced tests remain expensive, limiting access in lower-income areas.
Regulatory & Ethical Concerns: Issues around data privacy, informed consent, and usage of genetic information could slow market expansion.
Insufficient Genetic Counseling: A shortage of trained genetic counselors hampers effective interpretation and application of test results.
The report provides extensive insights into market size, segment breakdown, technological trends, regional penetration, key players, strategic initiatives, and future market predictions.
The market includes a robust mix of global leaders (Hoffmann-La Roche, Illumina, Thermo Fisher Scientific) and strong specialized firms (Myriad Genetics, QIAGEN, Oxford Nanopore Technologies). Competition hinges on proprietary technologies, regulatory approvals, and global partnerships.
Services Segment: Led the market in 2024, driven by the outsourcing of testing, laboratory networks, and comprehensive test packages.
Products Segment: Includes diagnostic kits, reagents, software, and platforms.
Oncology: Dominates the market, as genetic testing plays a critical role in cancer detection, prognosis, and treatment guidance.
Inherited & Rare Diseases
Pharmacogenomics
Other Applications: Cardiovascular risk profiling, reproductive health, pathogen detection.
Next-Generation Sequencing (NGS)
PCR
Microarrays
Others: Sanger sequencing, cytogenetics.
North America: Held a 41.7% market share in 2024 (~USD 14.11 billion). Dominance driven by advanced infrastructure, reimbursement frameworks, and leading players .
Europe: Strong growth, spurred by improved healthcare funding, strategic collaborations, and rising personalized medicine usage.
Asia-Pacific: Fastest-growing region, due to growing awareness, better testing infrastructure, and large patient populations.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/genetic-testing-service-market-105590
The genetic testing market is poised for continued growth thanks to:
Faster, cheaper sequencing platforms and point-of-care diagnostic tools.
Broader use in emerging fields like pharmacogenomics, expanded newborn screening, and prenatal testing.
Digital and AI tools for test interpretation and automated analytics.
Greater penetration of direct-to-consumer testing platforms.
More robust regulatory frameworks ensuring data protection and test quality.
The genetic testing market is at the nexus of modern healthcare evolution, combining technology, diagnostics, and personalized treatment. With projections reaching USD 76.09 billion by 2032 and a robust CAGR of 10.7%, the industry stands on the brink of transformative growth. Stakeholders can benefit from ongoing innovation, strategic collaborations, and expanding global awareness. While regulatory, cost, and ethical challenges remain, the opportunity to integrate genetics into routine clinical practice and empower patient care is immense.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com